Evidence map›Paper›PMID 26489424›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2016

Landscape of early clinical trials for childhood and adolescence cancer in Spain.

F Bautista, S Gallego, A Cañete, J Mora, C Diaz de Heredia, O Cruz, J M Fernández, S Rives, L Madero, V Castel and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Article
  4. ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 1 country.

F BautistaCNIO-HNJ Clinical Research Unit, Servicio de Onco-Hematologia y Transplante, Pediatric Oncology, Hematology and Stem Cell Transplant Department, Hospital Infantil Universitario Niño Jesús, Avenida Menéndez Pelayo, 65, 28009, Madrid, Spain.
S GallegoHospital Vall d'Hebron, Barcelona, Spain.
A CañeteHospital Universitario y Politécnico La Fe, Valencia, Spain.
J MoraHospital Sant Joan de Déu, Barcelona, Spain.
C Diaz de HerediaHospital Vall d'Hebron, Barcelona, Spain.
O CruzHospital Sant Joan de Déu, Barcelona, Spain.
J M FernándezHospital Universitario y Politécnico La Fe, Valencia, Spain.
S RivesHospital Sant Joan de Déu, Barcelona, Spain.
L MaderoCNIO-HNJ Clinical Research Unit, Servicio de Onco-Hematologia y Transplante, Pediatric Oncology, Hematology and Stem Cell Transplant Department, Hospital Infantil Universitario Niño Jesús, Avenida Menéndez Pelayo, 65, 28009, Madrid, Spain.
V CastelHospital Universitario y Politécnico La Fe, Valencia, Spain.
M E CelaHospital Gregorio Marañón, Madrid, Spain.
G RamírezHospital Virgen del Rocío, Sevilla, Spain.
C SábadoHospital Vall d'Hebron, Barcelona, Spain.
T AchaHospital Carlos Haya, Málaga, Spain.
I AstigarragaHospital Universitario Cruces, Bilbao, Spain.
A SastreHospital La Paz, Madrid, Spain.
A MuñozHospital Miguel Servet, Zaragoza, Spain.
M GuibelaldeHospital Universitario Son Espases, Palma de Mallorca, Spain.
L MorenoCNIO-HNJ Clinical Research Unit, Servicio de Onco-Hematologia y Transplante, Pediatric Oncology, Hematology and Stem Cell Transplant Department, Hospital Infantil Universitario Niño Jesús, Avenida Menéndez Pelayo, 65, 28009, Madrid, Spain. lmorenom@ext.cnio.es.
Hospital Sant Joan de Déu Barcelona · ESHospital Universitari i Politècnic La Fe · ESVall d'Hebron Hospital Universitari · ESHospital Infantil Universitario Niño Jesús · ESHospital de Cruces · ESHospital Doctor José Molina Orosa · ESHospital General Universitario Gregorio Marañón · ESHospital Universitario de La Princesa · ESHospital Universitario La Paz · ESHospital Universitario Miguel Servet · ESHospital Universitario Son Espases · ESHospital Universitario Virgen del Rocío · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDespite numerous advances, survival remains dismal for children and adolescents with poor prognosis cancers or those who relapse or are refractory to first line treatment. There is, therefore, a major unmet need for new drugs. Recent advances in the knowledge of molecular tumor biology open the door to more adapted therapies according to individual alterations. Promising results in the adult anticancer drug development have not yet been translated into clinical practice. We report the activity in early pediatric oncology trials in Spain.

methodsAll members of the Spanish Society of Pediatric Hematology Oncology (SEHOP) were contacted to obtain information about early trials open in each center.

results22 phase I and II trials were open as of May 2015: 15 for solid tumors (68 %) and 7 for hematological malignancies (32 %). Fourteen (64 %) were industry sponsored. Since 2010, four centers have joined the Innovative Therapies For Children With Cancer, an international consortium whose aim is developing novel therapies for pediatric cancers. A substantial number of studies have opened in these 5 years, improving the portfolio of trials for children. Results of recently closed trials show the contribution of Spanish investigators, the introduction of molecularly targeted agents and their benefits.

conclusionsClinical trials are the way to evaluate new drugs, avoiding the use of off-label drugs that carry significant risks. The Spanish pediatric oncology community through the SEHOP is committed to develop and participate in collaborative academic trials, to favor the advancement and optimization of existing therapies in pediatric cancer.

Indexed as

Clinical Trials as TopicAdolescentChildFemaleHumansMaleMedical OncologyNeoplasmsPediatricsSpainDrug developmentEarly phase clinical trialsPediatric hematology and oncologyPersonalized medicine

Identifiers

PMID26489424
OpenAlexW2177378057

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.